Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX

The VEGF‐A monoclonal antibody bevacizumab is currently recommended for first‐line treatment of all metastatic colorectal cancer (mCRC) patients. Cost‐benefit ratio and side‐effects however necessitate patient selection. A large retrospective yet nonrandomized study showed that patients with loss of...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dijk, Erik, van Werkhoven, Erik, Asher, Rebecca, Mooi, Jennifer K., Espinoza, David, van Essen, Hendrik F., van Tinteren, Harm, van Grieken, Nicole C. T., Punt, Cornelis J. A., Tebbutt, Niall C., Ylstra, Bauke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545440/
https://www.ncbi.nlm.nih.gov/pubmed/35489024
http://dx.doi.org/10.1002/ijc.34061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545440/
https://www.ncbi.nlm.nih.gov/pubmed/35489024
http://dx.doi.org/10.1002/ijc.34061

Ejemplares similares